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Abstract
Background: Impaired glucose tolerance (IGT) is a pre-diabetic state of hyperglycemia that is associated with
insulin resistance, increased risk of type II diabetes, and cardiovascular pathology. Recently, investigators
hypothesized that decreased vagus nerve activity may be the underlying mechanism of metabolic syndrome
including obesity, elevated glucose levels, and high blood pressure.
Methods: In this pilot randomized clinical trial, we compared the efficacy of transcutaneous auricular vagus nerve
stimulation (taVNS) and sham taVNS on patients with IGT. 72 participants with IGT were single-blinded and were
randomly allocated by computer-generated envelope to either taVNS or sham taVNS treatment groups. In addition,
30 IGT adults were recruited as a control population and not assigned treatment so as to monitor the natural
fluctuation of glucose tolerance in IGT patients. All treatments were self-administered by the patients at home after
training at the hospital. Patients were instructed to fill in a patient diary booklet each day to describe any side
effects after each treatment. The treatment period was 12 weeks in duration. Baseline comparison between
treatment and control group showed no difference in weight, BMI, or measures of systolic blood pressure, diastolic
blood pressure, fasting plasma glucose (FPG), 2-hour plasma glucose (2hPG), or glycosylated hemoglobin (HbAlc).
Results: 100 participants completed the study and were included in data analysis. Two female patients (one in the
taVNS group, one in the sham taVNS group) dropped out of the study due to stimulation-evoked dizziness. The
symptoms were relieved after stopping treatment. Compared with sham taVNS, taVNS significantly reduced the
two-hour glucose tolerance (F(2) = 5.79, p = 0.004). In addition, we found that taVNS significantly decreased
(F(1) =4.21, p= 0.044) systolic blood pressure over time compared with sham taVNS. Compared with the
no-treatment control group, patients receiving taVNS significantly differed in measures of FPG (F(2) = 10.62,
p< 0.001), 2hPG F(2)= 25.18, p <0.001) and HbAlc (F(1)= 12.79, p = 0.001) over the course of the 12 week treatment
period.
Conclusions: Our study suggests that taVNS is a promising, simple, and cost-effective treatment for IGT/
pre-diabetes with only slight risk of mild side-effects.
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Pre-diabetes, defined as impaired glucose tolerance (IGT),
or impaired fasting glucose (IFG) or both, represents an
intermediate state between normal glucose homeostasis
and diabetes [1]. IGT is a pre-diabetic state of hypergly-
cemia that is associated with insulin resistance and in-
creased risk of cardiovascular pathology. In patients with
IGT, the main site of insulin resistance is muscle tissue; this
is in contrast to another state of hyperglycemia, IFG, in
which the site of insulin resistance is the liver [1]. IGT af-
fects about 11% of people aged 20–74 years in the United
States [2]and 17% of those aged 40–65 years in Britain [3].
The American Diabetes Prevention Program (DPP) showed
that approximately 10% of individuals with IGT developed
diabetes on an annual basis [4]. In another study, investiga-
tors found that 30% of patients with IGT developed dia-
betes over a period of 8 years [5]. In a 10 year follow up
study, results showed that 15% of people with IGT devel-
oped non-insulin dependent diabetes and 22% remained
glucose intolerant [6]. Although patients with transient IGT
can revert to normal, they remain at increased long term
risk of developing non-insulin dependent diabetes. By the
time they develop diabetes, 50% will already have estab-
lished complications, 16% coronary artery disease, and 30%
retinopathy [7].
Current opinion suggests that pre-diabetes should be
treated either with lifestyle interventions, which target
obesity and physical inactivity, and/or with pharmaco-
logical intervention based on anti-diabetic drugs, in
order to prevent progression to diabetes [1]. For both in-
terventions, compliance can be a serious problem, and
the long term effects of pharmacological interventions
remain to be tested [8].
In recent years, investigators have proposed the hypoth-
esis that adequate vagus nerve activity can reduce the risk
of metabolic syndromes such as obesity, elevated glucose
level and blood pressure [9]. Thus, increasing the activity
and firing of the vagus nerve by direct stimulation may pre-
vent metabolic syndromes such as obesity, and elevated
glucose levels and blood pressure [9]. However, the involve-
ment of surgery, the perioperative risks, and the potentially
significant side effects associated with surgery have limited
the application of classic vagus nerve stimulation methods
in the patient population.
More recently, investigators have implemented transcuta-
neous auricular vagus nerve stimulation (taVNS) in replace-
ment of the classic VNS method to treat disorders such as
epilepsy [10] and depression [11]. The rationale for using
taVNS is that anatomical studies have shown that the ear is
t h eo n l yp l a c eo nt h es u r f a c eo ft h eh u m a nb o d yw h e r e
there is afferent vagus nerve distribution [12]. Thus, direct
stimulation of the afferent vagus nerve fibers on the ear
may produce an effect similar to classic VNS without the
burden of surgical intervention [13].
In this study, we performed a pilot randomized clinical
trial to test the efficacy of taVNS in IGT patients.
Methods
This study was registered at the Chinese Cochrane
Centre, International Clinical Epidemiology Network Re-
source and Training Center (ChiCTR-TRC-12002522).
The Institutional Ethics Committee of the China Acad-
emy of Chinese Medical Sciences approved this study.
All clinical investigative procedures were conducted ac-
cording to the principles expressed in the Declaration of
Helsinki. All patients and healthy controls signed a con-
sent form prior to initiation of study procedures.
Study population
IGT outpatients were recruited from the China Academy
of Chinese Medical Sciences acupuncture hospital for a
randomized clinical trial to test the efficacy of taVNS. Sub-
ject recruitment and all study procedures were completed
between November 2009 and December 2010.
In order to monitor the natural fluctuation of glucose
tolerance in IGT patients, an additional 30 IGT patients
were recruited from free clinics in the community
through advertisements in the local newspaper and post-
ers. Patients in the no-treatment control group were re-
quired to fulfill the same inclusion criteria as patients
who were randomized to receive treatment. Recruitment
for the control population took place during the same
period of time as for the two treatment groups. The con-
trol population was included to explore the variation of
patient glucose levels under normal life conditions for
12 weeks without treatment.
All patients met the World Health Organization
(WHO) standard diagnosis of IGT [14], and additionally
were required to meet all of the following inclusion
criteria:
a. Patients between 20 and 70 years of age
b. Levels of FPG less than 7.0 mmol/L and levels of
2hPG between 7.8 and 11.1 mmol/L at the time of
enrollment
c. Ability and willingness to provide informed consent
d. No history of serious infections in the previous
month.
Individuals were excluded from participation if they
fulfilled any of the following exclusion criteria:
a. Risk of serious cardiovascular and hematopoietic
system disease, or other serious primary diseases or
mental illnesses
b. Pregnant or lactating women
c. Use of hypoglycemic western medicine or insulin
treatment
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e. History of alcohol dependency or use of illicit drugs.
Randomization
This study was designed as a single blind randomized
controlled trial (RCT). After screening, 72 IGT participants
were randomly assigned to either the transcutaneous aur-
icular vagus nerve stimulation group (taVNS) or sham
taVNS group (randomization sequence created using SAS
System 7.0). All randomization assignments were pre-
packed in envelopes and consecutively numbered for each
participant according to the randomization schedule. All
participants were blinded to their treatment modality and
received the randomly-assigned intervention, as described
in the envelope, until the end of the study.
Intervention
After group randomization, all patients received training
at the hospital regarding how to use the Transcutaneous
Electrical Nerve Stimulator device to apply stimulation.
All subsequent treatments were self-administered by the
patients at home. Patients were also instructed to
complete a patient diary booklet each day to describe
any side effects corresponding with or temporally related
to treatment. The investigators checked all booklets at
the 6 and 12-week assessments.
taVNS treatment
Location
The points for taVNS are located in the auricular concha
area where there is rich vagus nerve branch distribution
(Figure 1).
Intervention procedure
taVNS was applied using a Huatuo ear vagus nerve
stimulator (TENS-200) developed by Suzhou manufac-
ture of Medical Device and Material (see Figure 2).
Stimulation parameters for both the taVNS and sham
taVNS groups were 1 mA of electrical current at a fre-
quency of 20 Hz with pulse duration≤ 1m s ,a d m i n i s -
tered twice daily. The intensity was adjusted based on
the individual tolerance of patients. Each postprandial
treatment lasted 20 minutes and was applied half of an
hour after eating. After the training session, all subse-
quent treatments were applied independently by the pa-
t i e n ta th o m e .
Sham taVNS treatment
Location
The stimulation points for sham taVNS are located at
the superior scapha (the midpoint of the outer ear
margin), where we expect no vagus nerve distribution
(Figure 1) based on previous studies [12].
Intervention procedure
All procedures performed in the sham taVNS treatment
group were identical to those performed for the taVNS
group, with the exception of the altered location of
stimulations.
Figure 1 Location of taVNS and sham taVNS. Red dots indicate
locations of taVNS, blue dots indicate the location of sham taVNS.
Figure 2 Ear vagus nerve stimulator used for taVNS.
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All patients in the no-treatment control group were re-
cruited from community free clinics that provide free
physical exams, including blood glucose testing. No
taVNS or sham taVNS treatments were applied.
Outcome measurements
The primary outcome measure of this study is the
change in 2hPG levels measured at baseline, 6-weeks,
and 12-weeks. Secondary outcomes include changes in
FPG levels, HbAlc levels, BMI (Body Mass Index) and
blood pressure (assessed at baseline and 12-weeks). All
measures of blood glucose were measured by the Glu-
cose Oxidase method (BaiAnyi, Bayer HealthCare LLC.).
Statistical analysis
Our analyses were based on the intention-to-treat
principle. Statistical analysis was performed using SPSS
19.0 Software (SPSS Inc., Chicago, IL, USA). Repeated
measurements were applied to compare primary and
secondary outcomes. First, we compared the taVNS and
sham taVNS groups; then, we separately compared real
and sham taVNS with the no-treatment control popula-
tion, to further assess and isolate the treatment effects of
taVNS and sham taVNS.
Results
A total of 102 participants completed the study (72 fe-
males, 54.4 ±7.4 years (mean ±SD), range: 33–68). Two
female patients (one in the taVNS group and one in the
sham taVNS group) dropped out of the study due to
stimulation-evoked dizziness. The symptoms were re-
lieved after stopping treatment. All other participants re-
ported following all treatment instructions with a
reported compliance rate of 98.04%. Figure 3 details the
recruited and excluded participants.
Comparison between the taVNS and sham taVNS
Comparison by Independent Samples t-test showed that
the two groups did not differ in age (t(70)=1.51, p=0.14),
weight (t(70) = −0.83, p=0.41) systolic blood pressure
(t(70) =1.42, p=0.16), diastolic blood pressure (t(70) =0.22,
p=0.16), or BMI (t(70) =64.07, p=0.61) at baseline
(Table 1). The gender distribution also did not differ signifi-
cantly across groups (χ
2 (2, n =72) =3.29, p=0.07). Mea-
sures of FPG (t( 70 )=0 . 3, p=0 .7 7 ), 2 h PG ( t(70) =1.96,
p=0.054) and HbAlc (t(70) =1.12, p=0.27) similarly did
not differ between groups at baseline.
Comparison of the taVNS and sham taVNS groups using
repeated measures analysis of variance (ANOVA) indicated
a significant difference in 2hPG between groups over the
Figure 3 The Flow diagram shows detailed information regarding recruited and excluded participants.
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and Table 2). The decrease in 2hPG was significantly
greater in the taVNS group compared to that in the sham
taVNS group (Table 3). After adjusting for age, gender, and
BMI, the effect remained significant (Table 2). Measures of
FPG (FGG (1.84) =2.48, p=0.093) and HbAlc (F(1)=0.23,
p=0.63) did not differ significantly between the taVNS and
sham taVNS groups over time in both crude analysis and
after adjusting for age, gender, and BMI (Table 2). For FPG,
Mauchly’s Test of Sphericity indicated that assumptions of
sphericity were violated, thus Greenhouse Geisser corrected
degrees of freedom were used.
Further analysis of other secondary outcomes indicated
that the taVNS and sham taVNS groups differed signifi-
cantly in systolic blood pressure over time (F(1)=4.21, p=
0.044). In the taVNS group, systolic blood pressure dropped
from 123.69±14.14 (mean±SD) to 118.64 ±13.34, while in
the sham taVNS group, systolic blood pressure remained at
119 ± 12. No significant differences were observed for
changes in diastolic blood pressure (F(1) =0.75, p=0.39) or
BMI (F(1) =0.069, p=0.79).
Comparison between taVNS, sham taVNS and no-
treatment control
In this study, we added a separate no-treatment control
group recruited from a free community clinic physical
exam program. This group was included to better under-
stand the natural fluctuation of outcomes in patients with
IGT and to isolate the pure treatment effects from other
naturally occurring factors.
Analysis of variance indicated that the three experimental
groups did not differ in age (F(2) = 1.95, p =0.15), weight
(F(2)=0.85,p=0.43), diastolic blood pressure (F(2)=1.05,
p=0.37), gender distribution (χ
2(2, n=102) =3.29, p=0.2),
or BMI (F(2) = 2.96, p = 0.057) at baseline. Measures of
FPG (F(2)=2.86, p=0.06), 2hPG (F(2)=2.03, p=0.14) and
HbAlc (F(2)=1, p=0.37) also did not differ between
groups at baseline. There was, however, a significant differ-
ence in systolic blood pressure (F(1) =1.02, p = 0.01).
Repeated measures ANOVA between the taVNS and
no-treatment control indicated significant differences in
FPG (F(2) =10.62, p< 0.001), 2hPG (F(2) =25.18,
p<0.001) and HbAlc (F(1) =12.79, p=0.001) between
groups over the course of the 12 weeks. All effects
remained significant after adjusting for age, gender, and
BMI (Table 4).
Analysis of other secondary outcomes, with compari-
son between the taVNS and no-treatment control
groups, indicated that there were no significant differ-
ences between the two groups in systolic blood pressure
(F(1) =0.99, p =0.32). diastolic blood pressure (F(1) =
1.27, p =0.27), or BMI (F(1) =0.003, p=0.96) over time.
Table 1 Baseline characteristics across three groups
Group Age Gender (M/F) Height Weight BMI
taVNS 55.3 (7.1) 7/29 1.6 (.06) 63.9 (11.7) 24.5 (3.5)
Sham taVNS 52.3 (8.7) 14/22 1.7 (.08) 66 (10.1) 23.9 (2.6)
Control 55.7 (5.6) 9/21 1.6 (.07) 67.2 (9) 25.7 (3.4)
All values are presented as mean (SD).
Figure 4 2-hour plasma glucose level changes among taVNS, sham taVNS and no-treatment control groups.
Table 2 Comparison of 2-hPG, FPG and HbAlc between
taVNS and sham taVNS groups
P-value Lower 95% CI Upper 95% CI
2hPG Crude .004 8.02 8.522
Adjusted .006 8.015 8.526
FPG Crude .093 5.946 6.203
Adjusted .11 5.948 6.201
HbAlc Crude .63 6.057 6.282
Adjusted .681 6.056 6.283
Adjusted values reflect age, gender, and BMI as covariates.
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and no-treatment control groups showed that the two
groups differed significantly in their levels of 2hPG
(FGG(1.72)=10.51, p<0.001) and HbAlc (F(1)=5.94,
p=.018) over the course of the experiment. Measures of
both 2hPG and HbAlc increased over the 12 weeks in the
control group, and decreased over the course of the
12 weeks in the sham taVNS treatment group. After con-
trolling for age, gender, and BMI, only the effect for
change in 2hPG remained significant (Table 5).
Analysis of other secondary outcomes between the
sham taVNS and no-treatment control indicated that
there were no significant differences between the two
groups in systolic blood pressure (F(1) =1.44, p=0.24),
diastolic blood pressure (F(1) =0.047, p= 0.83), or BMI
(F(1) =0.024, p=0.88) over time.
Safety
According to the patients’ booklet reports, we found that
2 patients reported feeling dizzy during or after applying
treatment. All participants recovered fully from the ad-
verse events after stopping the treatment.
Discussion
As the epidemic of diabetes continues to rise, it becomes
essential to develop and implement cost-effective preventa-
tive therapeutic strategies [8]. In this study, We compared
the efficacy of taVNS and sham taVNS in patients with
IGT. Results showed that compared with sham taVNS,
taVNS significantly reduced the two-hour glucose tolerance.
In addition, we found that taVNS significantly decreased
systolic blood pressure over time (F(1) = 4.21, p =0.044) as
compared with controls who received no treatment. Taken
together, our results suggest that taVNS demonstrates
potential use as a preventive treatment for pre-diabetes
or IGT.
The metabolic syndrome, which includes a constella-
tion of risk factors such as obesity, elevated lipids, and
elevated glucose and blood pressure, has increasingly
drawn attention from investigators; this syndrome is
regarded as both a disease and a risk factor for other
major diseases such as cardiovascular disease and
Alzheimer’s disease (AD) [9]. These diseases not only
harm our well-being and longevity, but also have a tre-
mendous economic impact [15]. Prevention and treat-
ment of these disorders require a considerable number
of medical resources. The discovery of a simple and
cost-effective method of controlling these disorders may
significantly benefit society.
Previous studies have suggested that the vagus nerve
plays an important role in maintaining metabolic homeo-
stasis. These studies further suggest that efferent vagus
nerve-mediated cholinergic signaling controls immune
function and proinflammatory responses via the inflamma-
tory reflex. Deregulation of metabolism and immune func-
tion are associated with chronic inflammation, which acts
as a critical step in the pathogenesis of insulin resistance
and type 2 diabetes mellitus [9,16].
In a previous study, investigators [17] found that meta-
bolic syndrome had an independent inverse association
with the vagal component of high-frequency heart rate
variability. In another study, Licht and colleagues [18]
found that decreased parasympathetic and increased
sympathetic activities are associated with increased like-
lihood of metabolic syndrome. Specifically, they found
Table 3 2-hPG, FPG and HbAlc before and after the
intervention across different groups
Ta-VNS Sham taVNS No-treatment
2hPG Baseline 9.7 (1.2) 9.1(1.2) 9.3 (1.1)
2hPG 6-weeks 7.3 (1.8)
** 8.0 (1.6)
** 9.5 (1.9)
2hPG 12-weeks 7.5 (1.3)
** 8.0 (1.4)
** 10.0 (2.7)
FPG Baseline 6.2 (0.6) 6.3 (0.5) 6.5 (0.3)
FPG 6-weeks 5.9 (0.8)
** 6.2 (0.8) 6.6 (0.8)
FPG 12-weeks 5.7 (0.6)
** 6.2 (0.8) 6.9 (1.2)
HbAlc Baseline 6.3 (0.5) 6.2 (0.6) 6.2 (0.4)
HBAlc 12-weeks 6.1 (0.4)
* 6.0 (0.4)
* 6.3 (0.6)
BMI Baseline 24.5 (3.5) 23.9 (2.6) 25.7 (3.4)
BMI 12-weeks 24.1 (3.3) 23.5 (2.6) 25.4 (3.0)
Compared to No-treatment group, *p < 0.05,* * p <0.01.
All values are presented as mean (SD).
Table 4 Comparison of 2-hPG, FPG and HbAlc between
taVNS and no-treatment control groups
P-value Lower 95% CI Upper 95% CI
2hPG Crude <.001 8.553 9.238
Adjusted <.001 8.546 9.241
FPG Crude <.001 6.164 6.473
Adjusted <.001 6.162 6.476
HbAlc Crude .001 6.123 6.346
Adjusted .002 6.124 6.342
Adjusted values reflect age, gender, and BMI as covariates.
Table 5 Comparison of 2-hPG, FPG and HbAlc between
the sham taVNS and no-treatment control groups
P-value Lower 95% CI Upper 95% CI
2hPG Crude <.001 8.63 9.336
Adjusted .003 8.636 9.294
FPG Crude .055 6.293 6.603
Adjusted .3 6.294 6.587
HbAlc Crude .018 6.051 6.285
Adjusted .07 6.052 6.247
Adjusted values reflect age, gender, and BMI as covariates.
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of parasympathetic activity in which high RSA reflects
high parasympathetic activity, was associated with glu-
cose levels and systolic blood pressure. Taken together,
these studies suggest that low vagus nerve activity may
underlie elevated glucose levels, which provides the bio-
logical mechanism of modulating IGT using taVNS.
Anatomical studies have shown that the ear is the only
place on the surface of the human body where there is
afferent vagus nerve distribution (12; 13). Thus, direct
stimulation of the afferent nerve fibers on the ear can regu-
late the activity of the vagus nerve, which can further regu-
late metabolic homeostasis. In this study, we found that
taVNS reduced both IGT and systolic blood pressure. This
result suggests that taVNS has the potential for use as a
therapeutic method for IGTand pre-diabetes, as well as po-
tentially for other metabolic syndromes.
In this study, we found that both taVNS and sham taVNS
significantly reduced the 2-hour glucose tolerance and
levels of HbAlc, indicating that sham taVNS could also pro-
duce a significant, and desirable, modulatory effect on glu-
cose levels. We speculate that this may be due to the strong
electrical stimulation at the sham point extending to the
adjacent area of the ear, where there is vagus nerve distribu-
tion. In addition, sham taVNS may produce these placebo
effects by influencing patient lifestyle. Patients were asked
to apply the postprandial treatment twice daily, which
might have reminded them to pay more attention to food
intake and levels of daily activity.
There are several limitations in this study. First, treat-
ments in the study were self-administered by the patients,
and thus patient compliance may have influenced the ob-
served results. To enhance compliance, all patients were re-
quired to complete daily entries into a diary that was
checked during assessments. More importantly, however,
this self-administration method provides direct evidence for
the feasibility of wide application of the method used within
the study. This shows promise in significantly reducing the
expenses associated with such a treatment. Secondly, the
treatment was only 12 weeks in duration, thus the results
obtained only represent its short or mid-term effects. Fur-
ther study is warranted to evaluate the long-term effects of
this treatment option. Thirdly, we only measured blood
glucose level at three time points (the baseline, after
6 weeks, and after 12 weeks) for statistic analysis. Since
blood glucose levels may be affected by the food intake of
the previous day, a more frequent measurement in the fu-
ture study may provide more reliable information for the
influence of treatment on blood glucose level. Finally, the
no-treatment control group was not included in the
randomization scheme, as were the other two treatment
groups. The participants constituting the control group
were also recruited from a different population. However,
the purpose of this group was to add another layer of
control to explore the effects of the different treatments;
thus, it should not influence the conclusions of this study.
Conclusions
In summary, this pilot study demonstrates that taVNS can
significantly reduce two-hour glucose tolerance and systolic
blood pressure. As a simple, cost-effective therapeutic
method with mild side effects, it demonstrates great poten-
tial in the treatment of pre-diabetes and associated meta-
bolic disorders.
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